Folate fluorescein isothiocyanate conjugate

Drug Profile

Folate fluorescein isothiocyanate conjugate

Alternative Names: EC-17; Folate receptor-alpha-targeted fluorescent agent - OnTarget Laboratories; Folate receptor-alpha-targeted imaging agent - OnTarget Laboratories; Folate-5-fluorescein isothiocyanate; Folate-FITC conjugate; Folate-fluorescein isothiocyanate; OTL-0038; OTL-38

Latest Information Update: 13 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Endocyte; Purdue University
  • Developer Centre for Human Drug Research; Indiana University School of Medicine; Leiden University Medical Center; On Target Laboratories; Purdue University; University of Pennsylvania
  • Class Cancer vaccines; Fluoresceins; Haptens; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung cancer; Ovarian cancer
  • Phase I Breast cancer; Pituitary cancer; Primary hyperparathyroidism; Renal cell carcinoma

Most Recent Events

  • 12 Jun 2017 On Target Laboratories plans a phase III trial for Ovarian cancer (Diagnosis) (NCT03180307)
  • 04 May 2017 Phase-II clinical trials in Lung cancer (Diagnosis) in USA (IV) (NCT02872701)
  • 05 Aug 2016 On Target Laboratories plans a phase II trial for Lung cancer (Diagnosis) in USA (NCT02872701)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top